UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 26, 2006
----------------
CYTOGEN CORPORATION
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 000-14879 22-2322400
------------------------------ ------------------------ -------------------
(State or Other Jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification No.)
650 College Road East, CN 5308, Suite 3100, Princeton, NJ 08540
--------------------------------------------------------- ------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (609) 750-8200
--------------
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF PRINCIPAL OFFICERS; COMPENSATORY ARRANGEMENTS OF
CERTAIN OFFICERS.
On October 26, 2006, Cytogen Corporation (the "Company") announced the
appointment of Kevin Bratton as the Company's new chief financial officer. A
finance executive with more than 35 years of experience in healthcare,
biotechnology and technology, Mr. Bratton was previously chief financial officer
at Metrologic Instruments, Inc. (NASDAQ: MTLG), a global technology company.
During his tenure at Metrologic, Mr. Bratton directed the company's finance
operations during a period of significant growth in sales, net income, cash flow
from operations, and working capital.
Prior to joining Metrologic Instruments, Mr. Bratton worked at The JPM
Company, where he served as chief financial officer from 2000 to 2002 and as
director of external reporting from 1999 to 2000. Prior to joining JPM, Mr.
Bratton worked for more than 20 years in the healthcare sector. He was vice
president finance and treasurer for the biotechnology company IGI, Inc., and
corporate controller for the specialty medical company Delmed, Inc. Mr. Bratton
began his career with the public accounting firm Touche Ross & Co. (now Deloitte
& Touche LLP). He has a bachelor of science in business and accounting from
Northeastern University.
The full text of the October 26, 2006 press release issued in connection
with the announcement is attached as Exhibit 99.1 to this Current Report on Form
8-K.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
Exhibit No. Description
----------- -----------
99.1 Press Release of the Company dated October 26, 2006.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
CYTOGEN CORPORATION
By: /s/ William J. Thomas
-------------------------------
William J. Thomas
Senior Vice President and
General Counsel
Dated: October 26, 2006
EXHIBIT INDEX
Exhibit No. Description
----------- -----------
99.1 Press Release of the Company dated October 26, 2006.